Thrivent Financial for Lutherans Sells 1,927 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS)

Thrivent Financial for Lutherans reduced its stake in shares of BioLife Solutions, Inc. (NASDAQ:BLFS) by 6.4% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 28,261 shares of the medical equipment provider’s stock after selling 1,927 shares during the period. Thrivent Financial for Lutherans owned 0.06% of BioLife Solutions worth $708,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Mutual of America Capital Management LLC acquired a new position in shares of BioLife Solutions in the 2nd quarter worth approximately $8,592,000. Vanguard Group Inc. lifted its holdings in BioLife Solutions by 11.5% in the first quarter. Vanguard Group Inc. now owns 2,868,335 shares of the medical equipment provider’s stock valued at $53,208,000 after buying an additional 296,727 shares during the period. Raymond James & Associates bought a new stake in BioLife Solutions during the second quarter valued at $2,876,000. Envestnet Asset Management Inc. boosted its position in BioLife Solutions by 261.5% during the second quarter. Envestnet Asset Management Inc. now owns 127,215 shares of the medical equipment provider’s stock valued at $2,726,000 after acquiring an additional 92,021 shares during the last quarter. Finally, Fred Alger Management LLC grew its holdings in BioLife Solutions by 6.0% during the 2nd quarter. Fred Alger Management LLC now owns 1,579,138 shares of the medical equipment provider’s stock worth $33,841,000 after acquiring an additional 88,840 shares during the period. 93.24% of the stock is owned by institutional investors and hedge funds.

BioLife Solutions Trading Down 1.7 %

NASDAQ BLFS opened at $26.81 on Wednesday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. BioLife Solutions, Inc. has a 52 week low of $12.45 and a 52 week high of $28.88. The business has a 50 day moving average price of $24.27 and a 200-day moving average price of $23.28.

Insider Buying and Selling at BioLife Solutions

In other BioLife Solutions news, EVP Aby J. Mathew sold 10,000 shares of BioLife Solutions stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $23.90, for a total transaction of $239,000.00. Following the completion of the transaction, the executive vice president now owns 317,716 shares in the company, valued at approximately $7,593,412.40. The trade was a 3.05 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CRO Garrie Richardson sold 3,070 shares of the stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $25.12, for a total value of $77,118.40. Following the completion of the sale, the executive now directly owns 114,773 shares of the company’s stock, valued at approximately $2,883,097.76. This trade represents a 2.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 71,313 shares of company stock worth $1,572,899. 2.20% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Northland Securities upped their target price on BioLife Solutions from $26.00 to $28.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. HC Wainwright cut their price target on BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a report on Monday, November 18th. Craig Hallum raised their price objective on shares of BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Finally, TD Cowen boosted their target price on shares of BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. According to MarketBeat, BioLife Solutions has a consensus rating of “Moderate Buy” and an average price target of $27.50.

BioLife Solutions Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.